Cervical cancer
Cervical cancer is the only gynecological malignancy with a clear etiology, and is associated with persistent infection with high-risk human papillomavirus. HPV is a double-stranded DNA virus that mainly infects the epithelium of the skin and mucous membranes, causing different lesions. Other high-risk factors include: 1. Sexual behavior: starting sexual life too early, multiple sexual partners; 2. Menstrual and childbirth factors: poor menstrual hygiene, prolonged menstruation, early childbearing, multiple births, etc.; 3. Smoking; 4. Long-term use of oral contraceptives, etc. The earliest symptoms are mainly vaginal bleeding and vaginal discharge. It is the third most common malignant tumor among women worldwide, second only to breast cancer and colorectal cancer.
-
Site of disease:
Uterus -
Infectious :
Not contagious -
Frequent population:
Women aged 40 to 60, in the sexually active period... -
Related symptoms:
Purulent and bloody leucorrhea weight loss nipple-like hyperplasia changes continuous vaginal bleeding vaginal metastasis -
Concurrent disease:
Related Drugs
GARDASIL 9- human papillomavirus 9-valent vaccine, recombinant_injection, suspension
Indication: GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58. 1 Genital warts (condyloma acuminata) caused by HPV types 6 and 11. 1 And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma in situ 1. 1 Cervical intraepithelial neoplasia (CIN) grade 1. 1 Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3. 1 Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3. 1 Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. 1 GARDASIL 9 is indicated in boys and men 9 through 45 years of age for the prevention of the following diseases: Anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58. 2 Genital warts (condyloma acuminata) caused by HPV types 6 and 11. 2 And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. 2 The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV- related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial ( 1 Vaccination with GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider. 3 17 GARDASIL 9 has not been demonstrated to provide protection against disease caused by: HPV types not covered by the vaccine HPV types to which a person has previously been exposed through sexual activity. 3 Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV 16, 18, 31, 33, 45, 52, and 58. 3 GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; CIN; VIN; VaIN; or AIN. 3 Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients. 3 GARDASIL registered Cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58 Genital warts (condyloma acuminata) caused by HPV types 6 and 11 And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma in situ Cervical intraepithelial neoplasia (CIN) grade 1 Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 GARDASIL 9 is indicated in boys and men 9 through 45 years of age for the prevention of the following diseases: Anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58 Genital warts (condyloma acuminata) caused by HPV types 6 and 11 And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease [see Clinical Studies (14. 5) Vaccination with GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider. GARDASIL 9 has not been demonstrated to provide protection against disease caused by: HPV types not covered by the vaccine [see Description (11) HPV types to which a person has previously been exposed through sexual activity. Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV 16, 18, 31, 33, 45, 52, and 58. GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; CIN; VIN; VaIN; or AIN. Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients.
Manufacturer:
Merck Sharp & Dohme LLC